Your Global Leader in Stem Cell Market Research
Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into mature cell types. Stem cell research and experimentation have been in process for well over five decades, as stem cells have the unique ability to divide and replicate repeatedly.
In this article:
Sadly, Novo Nordisk has ended its $598 million collaboration with Tokyo-based biotech Heartseed, marking a major shift in its approach to regenerative medicine and iPSCs, specifically. The cancelled partnership, originally launched in 2021, was focused on developing an allogeneic induced pluripotent stem cell (iPSC)-derived therapy for heart failure called “HS-001”.
Novo’s decision to terminate the deal, announced by Heartseed in a securities filing this week, was attributed to “strategic reviews and business shifts” under the company’s new CEO, Mike Doustdar. The move ends a four-year partnership that once represented a bold leap into regenerative medicine for Novo Nordisk. [Read more…]
Stem cell therapy has the potential to provide alternative treatment approaches to quite a few common and debilitating ailments. For example, stem cell transplants, called hematopoietic stem-cell transplantation (HSCT), are commonly used to support a cancer patient’s immune system. Likewise, stem cell treatments appears to be useful for a diverse range of applications, from the treatment of orthopedic injuries and arthritis to the treatment of neurodegenerative diseases.
Every year, research continues to find ways to utilize stem cells to improve the quality of life of patients. [Read more…]
Are you advancing an iPSC therapy program and planning for clinical-scale manufacturing of GMP Master Cell Banks (MCBs)? REPROCELL provides industry-standard, GMP-compliant iPSC MCB manufacturing services that support robust regulatory pathways without compromising quality or operational discipline. Through our European partnership with Histocell and its EMA-authorized facility in Bilbao, Spain, together with REPROCELL’s U.S. GMP site in Beltsville, Maryland, we offer a dual-site manufacturing network aligned with FDA, EMA, and PMDA expectations.
This infrastructure provides the scale, regulatory alignment, and global flexibility needed for allogeneic therapy programs moving to clinical translation without the excessive costs often linked to iPSC GMP manufacturing. [Read more…]
Biotech founder and CEO Jan Jensen has never been one for following the beaten track. As a young scientist studying the formation of insulin-producing pancreatic cells, Jensen questioned the prevailing view that these cells descended from neuroectoderm. His pancreatic embryonic tissue studies told him otherwise: insulin-producing pancreatic cells originate from within the pancreas itself. Jensen’s hypothesis, now the accepted view, and his further studies made him the first developmental biologist at Novo Nordisk, at a time when the world’s largest insulin producer had little interest in cell-based therapy. Now, 20 years later, Novo Nordisk is at the forefront of cell-based Type I Diabetes research. [Read more…]
